{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:45:40Z","timestamp":1771807540655,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10620-022-07789-x","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T10:12:19Z","timestamp":1670926339000},"page":"404-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn\u2019s Disease in Remission on Infliximab and Azathioprine"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-5877","authenticated-orcid":false,"given":"Gaurav","family":"Syal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil Y.","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher V.","family":"Almario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennan M. R.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"42","key":"7789_CR1","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","volume":"65","author":"JM Dahlhamer","year":"2016","unstructured":"Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged \u226518 years\u2014United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65(42):1166\u20131169.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"7789_CR2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med 2010;362(15):1383\u20131395.","journal-title":"N Engl J Med"},{"issue":"2","key":"7789_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146(2):392-400.e393.","journal-title":"Gastroenterology"},{"issue":"3","key":"7789_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","volume":"17","author":"L Beaugerie","year":"2019","unstructured":"Beaugerie L, Kirchgesner J. Balancing benefit vs risk of Immunosuppressive therapy for individual patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17(3):370\u2013379.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"7789_CR5","first-page":"289","volume":"11","author":"M Severs","year":"2017","unstructured":"Severs M, Oldenburg B, van Bodegraven AA, Siersema PD, Mangen MJ, Colitis ioCsa. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis 2017;11(3):289\u2013296.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"7789_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"ME van der Valk","year":"2014","unstructured":"van der Valk ME, Mangen MJ, Leenders M et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study. Gut 2014;63(1):72\u201379.","journal-title":"Gut"},{"key":"7789_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz104","author":"KT Park","year":"2019","unstructured":"Park KT, Ehrlich OG, Allen JI et al. The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis foundation. Inflamm Bowel Dis. 2019. https:\/\/doi.org\/10.1093\/ibd\/izz104.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"7789_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S2468-1253(19)30186-4","volume":"5","author":"TP Chapman","year":"2020","unstructured":"Chapman TP, Gomes CF, Louis E, Colombel JF, Satsangi J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2020;5(1):63\u201379.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7789_CR9","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1093\/ecco-jcc\/jjx002.052","volume":"11","author":"C Siegel","year":"2017","unstructured":"Siegel C, Thompson K, Walls D, Gollins J, Colombel J, Louis E. International differences in gastroenterologists\u2019 perspective on stopping therapy for patients with Crohn\u2019s disease. J Crohn\u2019s Colitis 2017;11:S34.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"1","key":"7789_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.crohns.2007.06.005","volume":"1","author":"S Ghosh","year":"2007","unstructured":"Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn\u2019s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis 2007;1(1):10\u201320.","journal-title":"J Crohns Colitis"},{"key":"7789_CR11","first-page":"CD012540","volume":"5","author":"RK Boyapati","year":"2018","unstructured":"Boyapati RK, Torres J, Palmela C et al. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn\u2019s disease. Cochrane Database Syst Rev 2018;5:CD012540.","journal-title":"Cochrane Database Syst Rev"},{"key":"7789_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz063","author":"K Bolin","year":"2019","unstructured":"Bolin K, Hertervig E, Louis E. The cost-effectiveness of biological therapy cycles in the management of Crohn\u2019s disease. J Crohns Colitis. 2019. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz063.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"7789_CR13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160(5):1570\u20131583.","journal-title":"Gastroenterology"},{"issue":"2","key":"7789_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/apt.14106","volume":"46","author":"X Roblin","year":"2017","unstructured":"Roblin X, Boschetti G, Williet N et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther 2017;46(2):142\u2013149.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"7789_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019;4(5):341\u2013353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"7789_CR16","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","volume":"63","author":"C Steenholdt","year":"2014","unstructured":"Steenholdt C, Brynskov J, Thomsen O et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63(6):919\u2013927.","journal-title":"Gut"},{"issue":"3","key":"7789_CR17","first-page":"760","volume":"104","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review. Am J Gastroenterol 2009;104(3):760\u2013767.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"7789_CR18","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.cgh.2014.01.033","volume":"12","author":"F Baert","year":"2014","unstructured":"Baert F, Drobne D, Gils A et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014;12(9):1474-1481.e1472.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"7789_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 2018;155(2):337-346.e310.","journal-title":"Gastroenterology"},{"issue":"17","key":"7789_CR20","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318(17):1679\u20131686.","journal-title":"JAMA"},{"key":"7789_CR21","unstructured":"Cancer stat facts: non-hodgkin lymphoma. https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed October 21, 2020"},{"key":"7789_CR22","unstructured":"Cancer Statistics at a Glance. https:\/\/gis.cdc.gov\/Cancer\/USCS\/#\/AtAGlance\/. Accessed October 21, 2020"},{"issue":"9","key":"7789_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371(9):796\u2013797.","journal-title":"N Engl J Med"},{"issue":"1","key":"7789_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40258-018-0432-4","volume":"17","author":"F Xu","year":"2019","unstructured":"Xu F, Liu Y, Wheaton AG, Rabarison KM, Croft JB. Trends and factors associated with hospitalization costs for inflammatory bowel disease in the United States. Appl Health Econ Health Policy 2019;17(1):77\u201391.","journal-title":"Appl Health Econ Health Policy"},{"key":"7789_CR25","unstructured":"Clinical Laboratory Fee Schedule. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched. Accessed October 21, 2020"},{"key":"7789_CR26","unstructured":"Research, Statistics, Data & Systems. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Research-Statistics-Data-and-Systems. Accessed October 21, 2020"},{"issue":"1","key":"7789_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1524-4733.2009.00661.x","volume":"13","author":"EC Mansley","year":"2010","unstructured":"Mansley EC, Carroll NV, Chen KS et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR drug cost task force report\u2013part III. Value Health 2010;13(1):14\u201317.","journal-title":"Value Health"},{"key":"7789_CR28","unstructured":"2020 ASP Drug Pricing Files. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2020-asp-drug-pricing-files. Accessed October 21, 2020."},{"issue":"7","key":"7789_CR29","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1080\/10428194.2017.1390230","volume":"59","author":"Q Chen","year":"2018","unstructured":"Chen Q, Staton AD, Ayer T, Goldstein DA, Koff JL, Flowers CR. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma 2018;59(7):1700\u20131709.","journal-title":"Leuk Lymphoma"},{"key":"7789_CR30","doi-asserted-by":"crossref","unstructured":"Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. https:\/\/www.ahrq.gov\/hai\/pfp\/haccost2017-results.html. Accessed October 21, 2020.","DOI":"10.1093\/med\/9780190862800.003.0004"},{"key":"7789_CR31","unstructured":"Costs for Hospital Stays in the United States, 2011. https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb168-Hospital-Costs-United-States-2011.pdf. Accessed October 21, 2020."},{"key":"7789_CR32","unstructured":"CPI Inflation Calculator. https:\/\/www.bls.gov\/data\/inflation_calculator.htm. Accessed December 20, 2020"},{"key":"7789_CR33","unstructured":"CEA Registry. http:\/\/healtheconomics.tuftsmedicalcenter.org\/cear2n\/search\/search.aspx. Accessed December 20, 2020"},{"issue":"2","key":"7789_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cgh.2019.11.062","volume":"19","author":"CA Siegel","year":"2021","unstructured":"Siegel CA, Thompson KD, Walls D et al. Perspectives from patients and gastroenterologists on de-escalating therapy for Crohn\u2019s disease. Clin Gastroenterol Hepatol 2021;19(2):403\u2013405.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"7789_CR35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","volume":"154","author":"G D'Haens","year":"2018","unstructured":"D\u2019Haens G, Vermeire S, Lambrecht G et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease. Gastroenterology 2018;154(5):1343-1351.e1341.","journal-title":"Gastroenterology"},{"issue":"7","key":"7789_CR36","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148(7):1320-1329.e1323.","journal-title":"Gastroenterology"},{"issue":"1","key":"7789_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","volume":"142","author":"E Louis","year":"2012","unstructured":"Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142(1):63-70.e65.","journal-title":"Gastroenterology"},{"issue":"11","key":"7789_CR38","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/ibd\/izy171","volume":"24","author":"E Shmidt","year":"2018","unstructured":"Shmidt E, Kochhar G, Hartke J et al. Predictors and management of loss of response to vedolizumab in inflammatory bowel disease. Inflamm Bowel Dis 2018;24(11):2461\u20132467.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"7789_CR39","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/apt.16802","volume":"55","author":"H Yang","year":"2022","unstructured":"Yang H, Li B, Guo Q et al. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther 2022;55(7):764\u2013777.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"7789_CR40","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/ecco-jcc\/jjaa087","volume":"14","author":"B Zhang","year":"2020","unstructured":"Zhang B, Gulati A, Alipour O, Shao L. Relapse from deep remission after therapeutic de-escalation in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2020;14(10):1413\u20131423.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"7789_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/apt.16714","volume":"55","author":"L Parrot","year":"2022","unstructured":"Parrot L, Dong C, Carbonnel F, Meyer A. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther 2022;55(4):380\u2013388.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"7789_CR42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1572-0241.2000.01779.x","volume":"95","author":"RD Cohen","year":"2000","unstructured":"Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn\u2019s disease. Am J Gastroenterol 2000;95(2):524\u2013530.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"7789_CR43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40273-016-0474-0","volume":"35","author":"K Fust","year":"2017","unstructured":"Fust K, Li X, Maschio M et al. Cost-effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-hodgkin lymphoma. Pharmacoeconomics 2017;35(4):425\u2013438.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"7789_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ecco-jcc\/jjz212","volume":"14","author":"FI Scott","year":"2020","unstructured":"Scott FI, Luo M, Shah Y et al. Identification of the most cost-effective position of vedolizumab among the available biologic drugs for the treatment of ulcerative colitis. J Crohns Colitis 2020;14(5):575\u2013587.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"7789_CR45","first-page":"369","volume":"26","author":"A Vasudevan","year":"2020","unstructured":"Vasudevan A, Ip F, Liew D, van Langenberg DR. The cost-effectiveness of initial immunomodulators or infliximab using modern optimization strategies for Crohn\u2019s disease in the biosimilar era. Inflamm Bowel Dis 2020;26(3):369\u2013379.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07789-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:56:41Z","timestamp":1675843001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07789-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7789"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07789-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GS has received research support from Pfizer. GYM has served as a consultant to Abbvie, Arena, Boehringer-Ingelheim, Bristol-Meyer Squibb\/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, Techlab; and received research funding from Pfizer. CVA has served as a consultant for Arena Pharmaceuticals and received grant support from Pfizer. BMRS has served as a consultant for Ironwood, Johnson & Johnson, Takeda, and Salix Pharmaceuticals, and has received research support from Amgen, Bausch, Ironwood, Pfizer, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}